Quarry LP Acquires Shares of 9,826 PetMed Express, Inc. (NASDAQ:PETS)

Quarry LP bought a new position in PetMed Express, Inc. (NASDAQ:PETS) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 9,826 shares of the company’s stock, valued at approximately $47,000.

Other institutional investors also recently modified their holdings of the company. Arrowstreet Capital Limited Partnership grew its holdings in PetMed Express by 26.5% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 513,381 shares of the company’s stock worth $2,474,000 after purchasing an additional 107,614 shares during the period. JPMorgan Chase & Co. grew its stake in shares of PetMed Express by 355.5% in the 4th quarter. JPMorgan Chase & Co. now owns 106,954 shares of the company’s stock worth $516,000 after buying an additional 83,473 shares during the last quarter. Diametric Capital LP bought a new position in PetMed Express during the 4th quarter valued at approximately $86,000. Boothbay Fund Management LLC purchased a new position in PetMed Express during the fourth quarter valued at $59,000. Finally, Virtu Financial LLC bought a new stake in PetMed Express in the fourth quarter worth $58,000. 73.33% of the stock is currently owned by institutional investors.

PetMed Express Price Performance

PETS stock opened at $3.62 on Friday. The stock has a market capitalization of $74.77 million, a P/E ratio of 362.36 and a beta of 0.99. PetMed Express, Inc. has a 1-year low of $2.90 and a 1-year high of $6.85. The business has a fifty day moving average price of $3.72 and a 200-day moving average price of $4.44.

PetMed Express (NASDAQ:PETS) last posted its earnings results on Monday, February 10th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.02). PetMed Express had a net margin of 0.14% and a return on equity of 0.37%. As a group, analysts anticipate that PetMed Express, Inc. will post 0.19 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on PETS shares. StockNews.com lowered PetMed Express from a “buy” rating to a “hold” rating in a research report on Wednesday, April 23rd. Morgan Stanley dropped their target price on shares of PetMed Express from $3.50 to $3.20 and set an “underweight” rating on the stock in a research note on Thursday, April 17th.

Insider Activity at PetMed Express

In other PetMed Express news, CEO Sandra Yvette Campos sold 60,463 shares of the business’s stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $3.31, for a total transaction of $200,132.53. Following the completion of the sale, the chief executive officer now directly owns 578,524 shares in the company, valued at $1,914,914.44. The trade was a 9.46 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.10% of the stock is owned by insiders.

PetMed Express Profile

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.